The U.S. Department of State announced the expansion of its partnership with Gilead Sciences and The Global Fund to increase access to lenacapavir (LEN), a breakthrough HIV prevention medication.
LEN is a twice-yearly injectable medication, which has shown 99.9 percent effectiveness at preventing HIV in large-scale clinical trials. Expanding upon its initial market shaping investment in access to LEN, the State Department said it is now growing its commitment to reach an additional 1 million people in high-burden countries with the two-dose annual regimen. Following the announcement, the United States and The Global Fund are committed to reach three million people in high-burden countries with LEN by 2028.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.